Cancer Letters
Volume 299, Issue 1 , Pages 11-21 , 18 December 2010

Vasoactive intestinal peptide (VIP) induces malignant transformation of the human prostate epithelial cell line RWPE-1

  • Ana B. Fernández-Martínez

      Affiliations

    • Department of Biochemistry and Molecular Biology, University of Alcalá, 28871 Alcalá de Henares, Spain
    • ,
  • Ana M. Bajo

      Affiliations

    • Department of Biochemistry and Molecular Biology, University of Alcalá, 28871 Alcalá de Henares, Spain
    • ,
  • M. Isabel Arenas

      Affiliations

    • Department of Cell Biology and Genetics, University of Alcalá, 28871 Alcalá de Henares, Spain
    • ,
  • Manuel Sánchez-Chapado

      Affiliations

    • Department of Surgery, University of Alcalá, 28871 Alcalá de Henares, Spain
    • Department of Urology, Príncipe de Asturias Hospital, 28871 Alcalá de Henares, Spain
    • ,
  • Juan C. Prieto

      Affiliations

    • Department of Biochemistry and Molecular Biology, University of Alcalá, 28871 Alcalá de Henares, Spain
    • Corresponding Author InformationCorresponding author. Tel.: +34 91 885 4527; fax: +34 91 885 4585.
    • ,
  • María J. Carmena

      Affiliations

    • Department of Biochemistry and Molecular Biology, University of Alcalá, 28871 Alcalá de Henares, Spain

Received 8 June 2010 ,Revised 20 July 2010 ,Accepted 22 July 2010.

References 

  1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics. CA Cancer J. Clin. 2009;59:225–249
  2. Guarino M, Rubino B, Ballabio G G. The role of epithelial–mesenchymal transition in cancer pathology. Pathology. 2007;39:305–318
  3. Lee JM, Dedhar S, Kalluri R, Thompson EW. The epithelial–mesenchymal transition: new insights in signalling, development, and disease. J. Cell Biol. 2006;172:973–981
  4. Arya M, Bott SR, Shergill IS, Ahmed HU, Willianson M, Patel HR. The metastatic cascade in prostate cancer. Surg. Oncol. 2006;15:117–128
  5. Zhau HE, Odero-Marah V, Lue HW, Nomura T, Wang R, Chu G, et al. Epithelial to mesenchymal transition (EMT) in human prostate cancer: lessons learned from ARCaP model. Clin. Exp. Metastasis. 2008;25:601–610
  6. Mol AJ, Geldof AA, Meijer GA, van der Poel HG, van Moorselaar RJ. New experimental markers for early detection of high-risk prostate cancer: role of cell–cell adhesion and cell migration. J. Cancer Res. Clin. Oncol. 2007;133:687–695
  7. Bello D, Webber MM, Kleinman HK, Wartinger DD, Rhim JS. Androgen responsive adult human prostatic epithelial cells and its loss by malignant cells. Carcinogenesis. 1997;18:1215–1223
  8. Kuettel MR, Thraves PJ, Jung M, Varghese SP, Prasad SC, Rhim JS, et al. Radiation-induced neoplastic transformation of human prostate epithelial cells. Cancer Res. 1996;1:5–10
  9. Prasad SC, Thraves PJ, Dritschilo A, Rhim JS, Kuettel MR. Cytoeskeletal changes during radiation-induced neoplastic transformation of human prostate epithelial cells. Scanning Microsc. 1996;10:1093–1102
  10. Li H, Gu Y, Miki J, Hukku B, McLeod D, Hei TK, et al. Malignant transformation of human benign prostate epithelial cells by high linear energy transfer alpha-particles. Int. J. Oncol. 2007;31:537–544
  11. Rhim JS, Jin S, Jung M, Thraves PJ, Kuettel MR, Webber MM, et al. Malignant transformation of human prostate epithelial cells by N-nitroso-N-methylurea. Cancer Res. 1997;80:576–580
  12. Nakamura K, Yasunaga Y, Ko D, Xu LL, Moul JW, Peehl DM, et al. Cadmium-induced neoplastic transformation of human prostate epithelial cells. Int. J. Oncol. 2002;20:543–547
  13. Achanzar WE, Diwan BA, Liu J, Quader S, Webber MM, Waalkes MP. Cadmium-induced malignant transformation of human prostate epithelial cells. Cancer Res. 2001;61:455–458
  14. Achanzar WE, Webber MM, Waalkes MP. Altered apoptotic gene expression and acquired apoptotic resistance in cadmium-transformed human prostate epithelial cells. Prostate. 2002;52:236–244
  15. Radisky DC, Kenny PA, Bissell MJ. Fibrosis and cancer: do myofibroblasts come also from epithelial cells via EMT?. J. Cell Biochem. 2007;101:830–839
  16. Polak JM, Bloom SR. Localisation and measurement of VIP in the genitourinary system of man and animal. Peptides. 1984;5:225–230
  17. Fernández-Martinez AB, Bajo AM, Sánchez-Chapado M, Prieto JC, Carmena MJ. Vasoactive intestinal peptide behaves as a pro-metastatic factor in human prostate cancer cells. Prostate. 2009;63:774–786
  18. Collado B, Gutiérrez-Cañas I, Rodríguez-Henche N, Prieto JC, Carmena MJ. Vasoactive intestinal peptide increases vascular endothelial growth factor expression and neuroendocrine differentiation in human prostate cancer LNCaP cells. Regul. Pept. 2004;119:69–75
  19. Fernández-Martínez AB, Collado B, Bajo AM, Sánchez-Chapado M, Prieto JC, Carmena MJ. Vasoactive intestinal peptide induces cyclooxygenase-2 expression through nuclear factor-κB in human prostate cell lines. Differential time-dependent responses in cancer progression. Mol. Cell. Endocrinol. 2007;270:8–16
  20. Juarranz MG, Bolaños O, Gutiérrez-Cañas I, Lerner EA, Robberecht P, Carmena MJ, et al. Neuroendocrine differentiation of the LNCaP prostate cancer cell line maintains the expression and function of VIP and PACAP receptors. Cell. Signal. 2001;13:887–894
  21. Gutiérrez-Cañas I, Rodríguez-Henche N, Bolaños O, Carmena MJ, Prieto JC, Juarranz MG. VIP and PACAP are autocrine factors that protect the androgen-independent prostate cancer cell line PC-3 from apoptosis induced by serum withdrawal. Brit. J. Pharmacol. 2003;139:1050–1058
  22. Sotomayor S, Carmena MJ, Schally AV, Varga JL, Prieto JC, Bajo AM. Transactivation of HER2 by vasoactive intestinal peptide in experimental prostate cancer: antagonistic action of an analog of growth-hormone-releasing hormone. Int. J. Oncol. 2007;31:1223–1230
  23. Collado B, Sánchez-Chapado M, Prieto JC, Carmena MJ. Hypoxia regulation of expression and angiogenic effects of vasoactive intestinal peptide (VIP) and VIP receptors in LNCaP prostate cancer cells. Mol. Cell. Endocrinol. 2006;249:116–122
  24. Bellyei S, Schally AV, Zarandi M, Varga JL, Vidaurre I, Pozsgai E. GHRH antagonists reduce the invasive and metastatic potential of human cancer cell lines in vitro. Cancer Lett. 2010;293:31–40
  25. Plonowski A, Schally AV, Busto R, Krupa M, Varga JL, Halmos G. Expression of growth hormone–releasing hormone (GHRH) and splice variants of GHRH receptors in human experimental prostate cancers. Peptides. 2002;23:1127–1133
  26. Letsch M, Schally AV, Busto R, Bajo AM, Varga JL. Growth hormone–releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers. Proc. Natl. Acad. Sci. USA. 2003;100:1250–1255
  27. Rekasi Z, Czompoly T, Schally AV, Boldizsar F, Varga JL, Zarandi M, et al. Antagonist of growth hormone–releasing hormone induces apoptosis in LNCaP human prostate cancer cells through a Ca2+-dependent pathway. Proc. Natl. Acad. Sci. USA. 2005;102:3435–3440
  28. Stangelberger A, Schally AV, Zarandi M, Heinrich E, Groot K, Havt A, et al. The combination of antagonists of LHRH with antagonists of GHRH improves inhibition of androgen sensitive MDA-PCa-2b and LuCaP-35 prostate cancers. Prostate. 2007;67:1339–1353
  29. Solano RM, Carmena MJ, Carrero I, Cavallaro S, Román F, Hueso C, et al. Characterization of vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptors in human benign hyperplastic prostate. Endocrinology. 1996;137:2815–2822
  30. Carmena MJ, Prieto JC. Cyclic AMP-stimulating effect of vasoactive intestinal peptide in isolated epithelial cells of rat ventral prostate. Biochim. Biophys. Acta. 1983;763:414–418
  31. Collado B, Carmena MJ, Sánchez-Chapado M, Ruíz-Villaespesa A, Bajo AM, Fernández-Martínez AB, et al. Expression of vasoactive intestinal peptide and functional VIP receptors in human prostate cancer: antagonistic action of a growth-hormone–releasing hormone analog. Int. J. Oncol. 2005;26:1629–1635
  32. Xie Y, Woll DW, Lin MF, Tu Y. Vasoactive intestinal peptide transactivates the androgen receptor through a protein-kinase A-dependent extracellular signal-regulated kinase pathway in prostate cancer LNCaP cells. Mol. Pharmacol. 2007;72:73–85
  33. Ekholm SV, Reed SI. Regulation of G(1) cyclin dependent kinases in the mammalian cell cycle. Curr. Opin. Cell Biol. 2000;12:676–684
  34. Collado B, Sánchez MG, Díaz-Laviada I, Prieto JC, Carmena MJ. Vasoactive intestinal peptide (VIP) induces c-fos expression in LNCaP prostate cancer cells through a mechanism that involves Ca2+ signalling. Implications in angiogenesis and neuroendocrine differentiation. Biochim. Biophys. Acta. 2005;1744:224–233
  35. Jamora C, Fuchs E. Intercellular adhesion, signaling and the cytoskeleton. Nat. Cell Biol. 2002;4:E101–E108
  36. Umbas R, Isaacs WB, Bringuier PP, Schaafsma HE, Karthaus HF, Oosterhof GO, et al. Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res. 1994;54:3929–3933
  37. Chin D, Boyle GM, Kane AJ, Theile DR, Hayward NK, Parson PG, et al. Invasion and metastasis markers in cancers. Brit. J. Plast. Surg. 2005;58:466–474
  38. Brehmer B, Biesterfeld S, Jakse G. Expression of matrix metalloproteinases (MMP-2 and -9) and their inhibitors (TIMP-1 and -2) in prostate cancer tissue. Prostate Cancer Prostatic Dis. 2003;6:217–222
  39. Zhang L, Shi J, Feng J, Klocker H, Lee C, Zhang J. Type IV collagenase (matrix metalloproteinase-2 and -9) in prostate cancer. Prostate Cancer Prostatic Dis. 2004;7:327–332
  40. Clark JCM, Thomas DM, Choong PFM, Dass CR. RECK – a newly discovered inhibitor of metastasis with prognostic significance in multiple forms of cancer. Cancer Metastasis Rev. 2007;26:675–683
  41. Islam S, Kim JB, Trendel J, Wheelock MJ, Johnson KR. Vimentin expression in human squamous carcinoma cells: relationship with phenotypic changes and cadherin-based cell adhesion. J. Cell Biochem. 2000;78:141–150
  42. Birchmeier W, Behrens J, Weidner KM, Hülsken J, Birchmeier C. Epithelial differentiation and the control of metastasis in carcinomas. Curr. Top. Microbiol. Immunol. 1996;213:117–135
  43. Benbrahim-Tallaa L, Webber MM, Waalkes MP. Mechanisms of acquired androgen independence during arsenic-induced malignant transformation of human prostate epithelial cells. Environ. Health Perspect. 2007;115:243–247
  44. Mellinghoff IK, Vivanco I, Kwon A, Tran C, Wongvipat J, Sawyers CL. HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell. 2004;6:517–527
  45. Rennebeck G, Martelli M, Kyprianou N N. Anoikis and survival connections in the tumor microenvironment: is there a role in prostate cancer metastasis?. Cancer Res. 2005;65:11230–11235
  46. Gobeil F, Fortier A, Zhu T, Bossolasco M, Leduc M, Grandbois M, et al. G-protein coupled receptors signaling at the cell nucleus: an emerging paradigm. Can. J. Physiol. Pharmacol. 2006;84:287–297
  47. Goetzl EJ. Diverse pathways for nuclear signaling by G protein-coupled receptors and their ligands. FASEB J. 2007;21:638–642
  48. Goetzl EJ. Hypothesis: VPAC G protein-coupled receptors for vasoactive intestinal peptide constitute a dynamic system for signaling T cells from plasma membrane and nuclear membrane complexes. Regul. Peptides. 2006;137:75–78

PII: S0304-3835(10)00378-2

doi: 10.1016/j.canlet.2010.07.019

Cancer Letters
Volume 299, Issue 1 , Pages 11-21 , 18 December 2010

Article Tools

* Image Usage & Resolution